General ENT News

ENT

sponsor

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Prenner B et al. - There were no significant differences between L/M and PSE for any efficacy analysis including improvement in the quality of life. Subjects treated with L/M experienced a similar incidence of total adverse events versus placebo and a lower incidence of total adverse events versus PSE. Nasal decongestant activity of L/M was significantly higher than that of placebo and similar to that of PSE in symptomatic AR subjects. L/M showed a safety profile similar to placebo and was better tolerated than PSE.


Today in Allergy...keeping you current

Oral Allergy Syndrome
Allergology International, 10/30/09

Montelukast in the treatment of asthma and beyond
Expert Review of Clinical Immunology, 11/23/09

Clinical Studies of Combination Montelukast and Loratadine in Patients with Seasonal Allergic Rhinitis
Journal of Asthma, 11/11/09

Today in Nose...keeping you current

Role of adenoids and adenoiditis in children with allergy and otitis media
Current Allergy and Asthma Reports, 10/22/09

Montelukast in the treatment of asthma and beyond
Expert Review of Clinical Immunology, 11/23/09

Saline Nasal Irrigation for Upper Respiratory Conditions
American Family Physician, 11/12/09